Fitness Trends Prostate Cancer Therapeutics Market | Page 2

• Prostate Cancer Therapeutics Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Prostate Cancer Therapeutics Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Rising implications associated with prostate cancer are expected to affect the prostate cancer
therapeutics market
Prostate cancer incidence is strongly related to age, with the highest incidence rates being in
older men. According to National Cancer Registry Ireland, 2011, median age at prostate cancer
diagnosis in Ireland was 67 years with 38.9% of cases being diagnosed in men and 21.3% in
men 75+ years. Median age at death was 80 with 70.3% of deaths occurring in men 75+ years.
Moreover, Supportive initiatives undertaken by key players in collaboration with various
governments to create more awareness of clinical symptoms about prostate cancer and
availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital
Rectal Exam (DRE) resulting in early detection are also the factors which expected to boost the
prostate cancer therapeutics market. However, high cost associated with drugs, and poor
reimbursement of treatment cost may affect the prostate cancer therapeutics negatively.
Endeavor to introduce highly effective therapies for prostate cancer would support the market
growth
Many research organizations and universities are investing in research for the development of
therapeutic products for the treatment of such tumors. For instance, some pipeline products
which are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin
(Mansoura University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the
market in the near future. Furthermore, many products that are about to face patent expiry
during the forecast period will also contribute in the growth of the generic prostate cancer
therapeutics market. Many pharmaceutical companies are also focusing on introducing their
respective drugs in different countries to boost the sales of their products. For instance, in
December, 2016, Sanofi’s prostate cancer drug name Jevtana (cabazitaxel) for the treatment of